|1.22||-0.01 / -0.81%|
Data as of Mar 14
|1.25||+0.03 / +2.46%|
The 2 analysts offering 12-month price forecasts for Rexahn Pharmaceuticals Inc have a median target of 2.75, with a high estimate of 3.00 and a low estimate of 2.50. The median estimate represents a +125.41% increase from the last price of 1.22.
The current consensus among 2 polled investment analysts is to Buy stock in Rexahn Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.